Pitavastatin improves serum resistin levels in patients with hypercholesterolemia

Journal of Atherosclerosis and Thrombosis

Volumn 15, Issue 2, 2008, Pages 87-93

  Ohbayashi, Hiroyuki ^a  

^a JA Gifu Tohno Kousei Hospital   (Japan)

Author keywords

Atherosclerosis; High sensitive C reactive protein (hsCRP); Pitavastatin; Resistin

Indexed keywords

EID: 47249146821     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E536     Document Type: Article

References (28)

1. Fasshauer M and Paschke R: Regulation of adipocytokines and insulin resistance. Diabetologia, 2003; 46:1594-1603
2. Steppan CM and Lazar MA: The current biology of resistin. J Intern Med, 2004; 255:439-447
3. Haluzik M and Haluzikova D: The role of resistin in obesity-induced insulin resistance. Curr Opin Investig Drugs, 2006; 7:306-311
4. Xu W, Yu L, Zhou W, and Luo M: Resistin increases lipid accumulation and CD36 expression in human macrophages. Biochem Biophys Res Commun, 2006; 351:376-382
5. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY, Kim SJ, Kim SY, Lee HK, and Park KS: Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res, 2006; 69:76-85
6. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, and Chen C: Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res, 2006; 70:146-157
7. Shin HJ, Park S, Yoon SJ, Choi DS, Cho DK, Kim JS, Ko YG, Choi D, Jang Y, and Chung N: Association between serum resistin and carotid intima media thickness in hypertension patients. Int J Cardiol, 2007 (in press)
8. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, and Catapano AL: Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol, 2007; 156:279-284
9. Pischon T, Bamberger CM, Kratzsch J, Zyriax BC, Algenstaedt P, Boeing H, and Windler E: Association of plasma resistin levels with coronary heart disease in women. Obes Res, 2005; 13:1764-1771
10. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, and Rader DJ: Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 2005; 111:932-939
11. Yoshitomi Y, Ishii T, Kaneki M, Tsujibayashi T, Sakurai S, Nagakura C, and Miyauchi A: Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb, 2006; 13:108-113
12. Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, and Shirai K: Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb, 2005; 12:163-168
13. Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM, and Hajjar DP: Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation, 2004; 110:3472-3479
14. Kawakami A, Tani M, Chiba T, Yui K, Shinozaki S, Nakajima K, Tanaka A, Shimokado K, and Yoshida M: Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism. Arterioscler Thromb Vasc Biol, 2005; 25:424-429
15. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, and Ehtesham NZ: Human resistin stimulates the proinflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun, 2005; 334:1092-1101
16. Rae C and Graham A: Human resistin promotes macrophage lipid accumulation. Diabetologia, 2006; 49:1112-1114
17. Kibayashi E, Urakaze M, Kobashi C, Kishida M, Takata M, Sato A, Yamazaki K, and Kobayashi M: Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond), 2005; 108:515-521
18. Jiang M, Bujo H, Zhu Y, Yamazaki H, Hirayama S, Kanaki T, Shibasaki M, Takahashi K, Schneider WJ, and Saito Y: Pitavastatin attenuates the PDGF-induced LR11/uPA receptor-mediated migration of smooth muscle cells. Biochem Biophys Res Commun, 2006; 348:1367-1377
19. Kaneyuki U, Ueda S, Yamagishi S, Kato S, Fujimura T, Shibata R, Hayashida A, Yoshimura J, Kojiro M, Oshima K, and Okuda S: Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation. Vascul Pharmacol, 2007; 46:286-292
20. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, and Okuda K: Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J Atheroscler Thromb, 2003; 10:37-42
21. Suzuki H, Kobayashi H, Sato F, Yonemitsu Y, Nakashima Y, and Sueishi K: Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb, 2003; 10:109-116
22. Ichida Y, Hasegawa G, Fukui M, Obayashi H, Ohta M, Fujinami A, Ohta K, Nakano K, Yoshikawa T, and Nakamura N: Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology, 2006; 76:34-39
23. Shetty GK, Economides PA, Horton ES, Mantzoros CS, and Veves A: Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care, 2004; 27:2450-2457
24. von Eynatten M, Schneider JG, Hadziselimovic S, Hamann A, Bierhaus A, Nawroth PP, and Dugi KA: Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care, 2005; 28:754-755
25. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL, Clark PM, Smith SA, Barnett AH, and Kumar S: Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab, 2003; 88:6098-6106
26. Yagmur E, Trautwein C, Gressner AM, and Tacke F: Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol, 2006; 101:1244-1252
27. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, Donnini D, Faggian D, Mussap M, Plebani M, Avellini C, Federspil G, Sechi LA, and Vettor R: Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab, 2006; 91:1081-1086
28. Bertolani C, Sancho-Bru P, Failli P, Bataller R, Aleffi S, DeFranco R, Mazzinghi B, Romagnani P, Milani S, Ginés P, Colmenero J, Parola M, Gelmini S, Tarquini R, Laffi G, Pinzani M, and Marra F: Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. Am J Pathol, 2006; 169:2042-2053